Psoriasis Treatment with Biologics
Existing TNF-inhbitors:
- Adalimumab (Abbott)
- Infliximab (Janssen Bitotech and other biosimilars (generics)
- Etanercept (Amgen)
- Certolizumab (UCB)
Il-17 antibodies
- Secukinumab (Cosentyx, Novartis):
- dosage: injected 300mg at weeks 0, 1, 2, 3, and 4 then 300mg or 150mg every 4 weeks, the doctor decides ! The price is the same for both doses !
Works in 3 weeks (vs 7 for etanercept)
- dosage: injected 300mg at weeks 0, 1, 2, 3, and 4 then 300mg or 150mg every 4 weeks, the doctor decides ! The price is the same for both doses !
- Ixekizumab (Eli Lilly) :
- 89.1% of treated individuals with psoriasis achieve a PASI 75 response ! (compared to 4% for the placebo group).
- By week 5, half of the treated individuals have achieved PASI75
- After week 1, there is already a statistically significant difference between cases and controls
- Brodalumab displays fast results which are comparable to Ixekizumab
Number Needed to Treat (NNT) is more forceful when talking what these new biologics do (compared to PASI):
- NNT is around 1.2 for Brodalumab and Ixekizumab vs 5 for Alefacept.
- This means that for 12 treated patients, 10 will achieve PASI 75. (Alefacept needed 50 patients to have 10 who achieved PASI75)
Contributors
Dr Christophe Hsu – dermatologist. Geneva, Switzerland
S002 – Leonardi C et al. Systemic Therapies for Dermatologists: a Comprehensive Review and Update. AAD 2015 Annual Meeting, San Francisco CA – United States
